Search

Displaying results 3771 - 3780 of 4600 in total
  1. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.

  2. Drug

    Sodium tetradecyl sulfate

    go.drugbank.com/drugs/DB00464
    Approved

    An anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins.

  3. Drug

    Apomorphine

    go.drugbank.com/drugs/DB00714
    ApprovedInvestigational

    Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an e...

  4. Drug

    Mesoridazine

    go.drugbank.com/drugs/DB00933
    ApprovedWithdrawn

    A phenothiazine antipsychotic with effects similar to chlorpromazine.

  5. Drug

    Aluminium phosphate

    go.drugbank.com/drugs/DB14517
    ApprovedInvestigational

  6. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    [A244705, A244710, A244745] Gantenerumab is a fully human IgG1κ monoclonal antibody derived from the MorphoSys HuCAL®-Fab1 phage display library and subsequently optimized by _in vitro_ CDR cassette

  7. Drug

    Poloxamer 407

    go.drugbank.com/drugs/DB11252
    Investigational

    It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature.

    Products: K-MOM Baby Tooth
  8. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists.

  9. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.

  10. Drug

    QR-334

    go.drugbank.com/drugs/DB05473
    Experimental

    Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. No pharmaceutical interventions currently exist to treat sialorrhea.